FDA to weigh easing limits on peptides promoted by RFK Jr. NBC 6 South Florida The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Issues Warning Letters Against Online GLP 1 Sellers BioSpace The Next Fountain of Youth Craze? Peptide Injections WSJ fda warning bpc 157 peptide products New Details 157